德谷门冬双胰岛素联合达格列净治疗2 型糖尿病疗效观察
|
谢冬生
|
江苏省滨海康达医院，江苏盐城，224500
|
摘要：目的 探究德谷门冬双胰岛素联合达格列净治疗2型糖尿病疗效。方法 将2023年1月至2024年12 月我院收治的80 例2 型糖尿病患者，随机分为观察组、对照组，各40 例。对照组、观察组分别实施德谷门冬双胰岛素治疗、德谷门冬双胰岛素联合达格列净治疗。结果 在治疗有效率方面，观察组为95.00%，对照组为75.00%，观察组明显高于对照组，有统计学意义（P ＜ 0.05）；在不良反应发生率方面，观察组为5.00%，对照组为27.50%，观察组明显低于对照组，有统计学意义（P ＜ 0.05）；在患者的生活质量方面，观察组精神健康、躯体功能、心理功能以及情感职能分别为（73.87±3.11）分、（73.87±3.73）分、（73.75±3.82）分、（73.98±2.82）分，观察组明显优于对照组，有统计学意义（P＜0.05）；结论 实施德谷门冬双胰岛素联合达格列净治疗在2型糖尿病患者中，能缓解胰岛素抵抗，增强胰岛素的敏感性，使德谷门冬双胰岛素更好地发挥作用，促进血糖达标，提升整体治疗效果，改善血管内皮功能、减少肾脏葡萄糖重吸收，从而减少不良反应的发生，提高了治疗依从性，使患者能更轻松地融入正常生活，改善生活质量评分，值得参考。
关健词：德谷门冬双胰岛素；达格列净；治疗；2型糖尿病
|
Observation on the therapeutic effect of Degu Aspartan dual insulin combined with Daggligin in the treatment of type 2 diabetes
|
Dongsheng Xie
Jiangsu Binhai Kangda Hospital, Yancheng Jiangsu 224500，China
|
Abstract：Objective To explore the efficacy of Degu Aspartan dual insulin combined with Daggligin in the treatment of type2 diabetes.Methods 80 patients with type 2 diabetes admitted to our hospital from January 2023 to December 2024 were randomlydivided into an observation group and a control group, with 40 cases in each group. The control group and observationgroup were respectively treated with double insulin therapy of Pueraria lobata and double insulin therapy of Pueraria lobata combinedwith dapagliflozin.Results In terms of treatment efficacy, the observation group was 95.00%, while the control groupwas 75.00%. The observation group was significantly higher than the control group, with statistical significance (P<0.05); Interms of the incidence of adverse reactions, the observation group was 5.00%, while the control group was 27.50%. The observationgroup was significantly lower than the control group, with statistical significance (P<0.05); In terms of patients’ quality oflife, the observation group’s mental health, physical function, psychological function, and emotional function were (73.87 ±3.11) points, (73.87 ± 3.73) points, (73.75 ± 3.82) points, and (73.98 ± 2.82) points, respectively. The observation group wassignificantly better than the control group, with statistical significance (P<0.05); Conclusion In patients with type 2 diabetes,the combination of Degu aspart insulin and Daggligin can alleviate insulin resistance, enhance insulin sensitivity, make Degu aspartinsulin play a better role, promote blood sugar to reach the standard, improve the overall treatment effect, improve vascularendothelial function, reduce renal glucose reabsorption, thus reducing the occurrence of adverse reactions, improving treatmentcompliance, making patients easier to integrate into normal life, and improving the quality of life score, which is worthy ofreference.
Keywords : Degu Mendong Double Insulin; Dapagliflozin; treatment; type 2 diabetes
|
|
|
论文收录证明 / 文献检索报告
Document Retrieval Certificate / Proof of Publication Indexing
作者贡献声明 / 贡献确认书
Author Contribution Statement / Certificate of Authorship Contribution
同行评审报告 / 评审意见
Peer Review Report / Peer Review Comments
利益冲突
Conflict of Interest
作者声明不存在任何利益冲突。
The author declares no conflict of interest.
|
|
